GlassScriptPhysician profile
Lidia M Navarro
NPI 1417428657
$6,656.69
in general payments reported to CMS, 2019-2025
30 companies · $1,404 in 2025
The $1,404 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2022: $1,861 · 2023: $1,531 · 2024: $1,604 · 2025: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,430 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,429.85 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,556.46 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $733.75 | 2022-2025 | |
| Dermavant Sciences, INC. | $494.22 | 2023-2024 | Vtama |
| Amgen INC. | $460.80 | 2021-2023 | Otezla, Enbrel |
| Genzyme Corporation | $399.37 | 2022-2024 | |
| Leo Pharma INC. | $317.90 | 2022-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $313.54 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $286.27 | 2022-2025 | Simponi Aria, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $258.99 | 2022-2025 | Winlevi, Absorica Ld, Odomzo |
| Pfizer INC. | $235.88 | 2022-2025 | |
| Lilly USA, LLC | $226.33 | 2021-2025 | Taltz, Ebglyss |
| Organon LLC | $180.69 | 2023-2025 | Vtama, Hadlima |
| Sanofi-Aventis U.S. LLC | $179.98 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $136.64 | 2022-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $131.19 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.32 | 2024-2025 | Jublia |
| Almirall LLC | $90.53 | 2022-2024 | Klisyri |
| Genentech USA, INC. | $90.15 | 2025 | Xolair |
| Ucb, INC. | $77.21 | 2022-2025 | Bimzelx |
| Boston Scientific Corporation | $75.12 | 2021-2022 | |
| Incyte Corporation | $64.21 | 2022-2024 | Opzelura |
| Kyowa Kirin, INC. | $39.72 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.13 | 2023 | Spevigo, Cyltezo |
| Botanix Sb INC | $36.87 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $32.83 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $26.75 | 2022-2025 | Nuzyra |
| Galderma Laboratories, L.P. | $22.41 | 2025 | Nemluvio |
| Celltrion USA INC. | $21.90 | 2024 | Vegzelma |
| Journey Medical Corporation | $19.79 | 2023 | |
| Scynexis, INC. | $14.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lidia Navarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.